Human TNBCs have a poor prognosis, because such cancers have no effective therapeutic targets, e.g. ER for endocrine therapy or human epidermal growth factor receptor 2 receptors for anti-HER2 therapy[35-37]. This evidence concerns the gene ERBB2 and cancer.